Additionally, TOP2A is a direct molecular target of topoisomerase inhibitor, and its upregulation has been reported in several cancers including lung, nasopharyngeal, esophageal, gallbladder, hepatocellular, colorectal, breast, endometrial, pancreatic and ovarian cancer [28–31]. This evidence concerns the gene TOP2A and ovarian carcinoma.